Loading clinical trials...

Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure | Clinical Trials | Clareo Health

TERMINATED

Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure

Consent for Obtaining Additional Bone Marrow Specimens at the Time of a Diagnostic Bone Marrow Procedure

NCT01048060•Stanford University

View on ClinicalTrials.gov

Summary

The purpose of this study is to collect bone marrow samples for experimental studies.

Eligibility

Age

0 - 21 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects who are having a bone marrow procedure done as part of their standard oncology work-up will be eligible to be consent on this study.

Exclusion Criteria

•None.

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Key Dates

Start Date

February 1, 2002

Primary Completion Date

August 1, 2015

Completion Date

August 1, 2016

Last Updated

February 11, 2019

Enrollment

334

ACTUAL participants

Conditions

Brain CancerCancer

Interventions

Bone marrow specimen banking

PROCEDURE

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149

Advanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+2 more

View study

RECRUITINGPHASE2

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure

Inclusion Criteria

Exclusion Criteria

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device